
Keywords: Bevacizumab; Breast cancer; Personalized medicine; Subgroup analysis; Multivariate statistical classification; Machine learning; FGF; fibroblast growth factor; FLT; fms-like tyrosine kinase; HER2; human epidermal growth factor receptor 2; MRST; in mean re